|
業務類別
|
Diagnostics & Research |
|
業務概覽
|
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flowcytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services. |
| 公司地址
| 3300 Nacogdoches Road, Suite 216, San Antonio, TX, USA, 78217 |
| 電話號碼
| +1 210 698-5334 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.bioaffinitytech.com |
| 員工數量
| 57 |
| Mr. Timothy P. Zannes, J.D. |
Executive Vice President, Secretary and General Counsel |
-- |
02/06/2025 |
| Ms. Maria Zannes, J.D. |
President, Chief Executive Officer and Director |
美元 330.00K |
16/03/2026 |
| Mr. J. Michael Edwards, C.P.A. |
Chief Financial Officer and Principal Accounting Officer |
美元 300.00K |
16/03/2026 |
| Mr. Xavier Trinidad Reveles |
Chief Operating Officer |
-- |
02/06/2025 |
|
|
| Mr. Robert A. Anderson |
Independent Director |
06/03/2026 |
| Mr. Steven Girgenti |
Executive Chairman of the Board |
16/03/2026 |
| Ms. Maria Zannes, J.D. |
President, Chief Executive Officer and Director |
16/03/2026 |
| Mr. Peter S. Knight |
Independent Director |
16/03/2026 |
| Mr. Roberto Rios, C.P.A. |
Independent Director |
16/03/2026 |
| Mr. John J. Oppenheimer, M.D. |
Independent Director |
16/03/2026 |
| Dr. Roby P. Joyce, M.D. |
Director |
06/03/2026 |
| Dr. Jamie Platt, PhD |
Independent Director |
16/03/2026 |
|
|
|
|
